PAG
BCLI

Private Advisor Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Private Advisor Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-405
Closed -$68K – 1742
2020
Q2 		$68K Buy
+405
New +$43.7K ﹤0.01% 1914

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Private Advisor Group's BCLI Position: Q3 2020 in Review

Private Advisor Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 405 shares — an estimated $68K sold.

Private Advisor Group first reported a position in BCLI in Q2 2020 and held it in 1 quarter. The position peaked at $68K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

  • Private Advisor Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 405 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $68K.
  • Private Advisor Group first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's BRAINSTORM CELL THERAPUTC position peaked at $68K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.